NO327973B1 - Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder - Google Patents

Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder Download PDF

Info

Publication number: NO327973B1
Authority: NO; Norway
Prior art keywords: use according; women; estrogen; estradiol; compound
Prior art date: 1999-10-25

Application number

NO20021949A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021949L (no

NO20021949D0 (no

Inventor

Jacques Paris

Jean-Louis Thomas

Original Assignee

Theramex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-25

Filing date

2002-04-25

Publication date

2009-11-02

2002-04-25 Application filed by Theramex filed Critical Theramex

2002-04-25 Publication of NO20021949L publication Critical patent/NO20021949L/no

2002-04-25 Publication of NO20021949D0 publication Critical patent/NO20021949D0/no

2009-11-02 Publication of NO327973B1 publication Critical patent/NO327973B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 19
239000003814 drug Substances 0.000 title claims description 8
238000004519 manufacturing process Methods 0.000 title claims description 8
208000024172 Cardiovascular disease Diseases 0.000 title claims description 7
208000001132 Osteoporosis Diseases 0.000 title claims description 7
229940079593 drug Drugs 0.000 title claims description 6
230000001076 estrogenic effect Effects 0.000 title claims description 6
230000002265 prevention Effects 0.000 title claims description 4
230000009245 menopause Effects 0.000 title description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
208000035475 disorder Diseases 0.000 title description 2
IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 33
229960004190 nomegestrol acetate Drugs 0.000 claims description 33
239000000583 progesterone congener Substances 0.000 claims description 33
229960005309 estradiol Drugs 0.000 claims description 28
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 26
229930182833 estradiol Natural products 0.000 claims description 26
239000000262 estrogen Substances 0.000 claims description 26
229940011871 estrogen Drugs 0.000 claims description 23
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 8
229960004911 nomegestrol Drugs 0.000 claims description 8
KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
241000283073 Equus caballus Species 0.000 claims description 6
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 3
-1 estradiol ester Chemical class 0.000 claims description 2
229960004766 estradiol valerate Drugs 0.000 claims description 2
230000000737 periodic effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 description 30
238000011282 treatment Methods 0.000 description 20
210000004696 endometrium Anatomy 0.000 description 15
238000009472 formulation Methods 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
230000000694 effects Effects 0.000 description 10
230000002357 endometrial effect Effects 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
238000009256 replacement therapy Methods 0.000 description 6
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 5
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
229960001616 chlormadinone acetate Drugs 0.000 description 5
230000003248 secreting effect Effects 0.000 description 5
230000009466 transformation Effects 0.000 description 5
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
206010051909 Endometrial atrophy Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
206010030247 Oestrogen deficiency Diseases 0.000 description 4
239000004372 Polyvinyl alcohol Substances 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
238000007907 direct compression Methods 0.000 description 4
239000008101 lactose Substances 0.000 description 4
229960004400 levonorgestrel Drugs 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
229920002451 polyvinyl alcohol Polymers 0.000 description 4
238000011285 therapeutic regimen Methods 0.000 description 4
150000000319 19-nortestosterones Chemical class 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000001548 androgenic effect Effects 0.000 description 3
230000001833 anti-estrogenic effect Effects 0.000 description 3
230000002927 anti-mitotic effect Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
201000006828 endometrial hyperplasia Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
206010061178 Genital haemorrhage Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229960002568 ethinylestradiol Drugs 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000002657 hormone replacement therapy Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 2
229960000606 medrogestone Drugs 0.000 description 2
229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
230000000757 progestagenic effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
239000002966 varnish Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010085330 Estradiol Receptors Proteins 0.000 description 1
102100038595 Estrogen receptor Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
206010067572 Oestrogenic effect Diseases 0.000 description 1
229920003071 Polyclar® Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
RUJWZZRJSQGFCW-OGPYDZPMSA-N [(8s,9s,10r,13s,14s,17r)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RUJWZZRJSQGFCW-OGPYDZPMSA-N 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000002054 antogonadotrophic effect Effects 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000005056 compaction Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008380 degradant Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
229960004913 dydrogesterone Drugs 0.000 description 1
230000000678 effect on lipid Effects 0.000 description 1
210000005168 endometrial cell Anatomy 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
235000013980 iron oxide Nutrition 0.000 description 1
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001207 micronized progesterone Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
150000003145 progesterone derivatives Chemical class 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
229940051201 quinoline yellow Drugs 0.000 description 1
235000012752 quinoline yellow Nutrition 0.000 description 1
239000004172 quinoline yellow Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000979 synthetic dye Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

NO20021949A 1999-10-25 2002-04-25 Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder NO327973B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/FR1999/002588 WO2001030356A1 (fr)	1999-10-25	1999-10-25	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
PCT/FR2000/002939 WO2001030357A1 (fr)	1999-10-25	2000-10-24	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation

Publications (3)

Publication Number	Publication Date
NO20021949L NO20021949L (no)	2002-04-25
NO20021949D0 NO20021949D0 (no)	2002-04-25
NO327973B1 true NO327973B1 (no)	2009-11-02

Family

ID=9542727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021949A NO327973B1 (no)	1999-10-25	2002-04-25	Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder

Country Status (27)

Country	Link
US (2)	US8168619B1 (pt)
EP (1)	EP1227814B1 (pt)
JP (1)	JP5036943B2 (pt)
KR (1)	KR100623788B1 (pt)
CN (1)	CN100553637C (pt)
AP (1)	AP1625A (pt)
AT (1)	ATE286400T1 (pt)
AU (1)	AU777704B2 (pt)
BR (1)	BRPI0014979B8 (pt)
CA (1)	CA2389025C (pt)
CZ (1)	CZ303248B6 (pt)
DE (1)	DE60017281T2 (pt)
DK (1)	DK1227814T3 (pt)
ES (1)	ES2235967T3 (pt)
HK (1)	HK1050472B (pt)
HU (1)	HU229382B1 (pt)
IL (2)	IL148953A0 (pt)
MX (1)	MXPA02004084A (pt)
NO (1)	NO327973B1 (pt)
NZ (1)	NZ518145A (pt)
OA (1)	OA12072A (pt)
PL (1)	PL199848B1 (pt)
PT (1)	PT1227814E (pt)
RU (1)	RU2261106C2 (pt)
SI (1)	SI1227814T1 (pt)
WO (2)	WO2001030356A1 (pt)
ZA (1)	ZA200203398B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754179B1 (fr)	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030356A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
FR2814074B1 (fr) *	2000-09-15	2003-03-07	Theramex	Nouvelles compositions estro-progestatives topiques a effet systemique
DE60217324T2 (de)	2001-05-18	2007-04-26	Pantarhei Bioscience B.V.	Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1390041B1 (en)	2001-05-23	2009-11-25	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US7732430B2 (en)	2001-05-23	2010-06-08	Pantarhei Bioscience B.V.	Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
ATE347365T1 (de) *	2001-11-15	2006-12-15	Pantarhei Bioscience Bv	Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
CA2489270C (en)	2002-06-11	2012-08-07	Pantarhei Bioscience B.V.	A method of treating human skin and a skin care composition for use in such a method
AU2003274946A1 (en)	2002-06-11	2003-12-22	Pantarhei Bioscience B.V.	Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
CN1662241A (zh) *	2002-06-25	2005-08-31	惠氏公司	环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途
US9034854B2 (en)	2002-07-12	2015-05-19	Pantarhei Bioscience B.V.	Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US8987240B2 (en)	2002-10-23	2015-03-24	Pantarhei Bioscience B.V.	Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CN101583363B (zh)	2007-01-08	2013-08-21	潘塔希生物科学股份有限公司	治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
CN107007611B (zh) *	2017-06-02	2020-04-14	上海市计划生育科学研究所	醋酸诺美孕酮在制备治疗子宫内膜癌的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826831A (en)	1983-08-05	1989-05-02	Pre Jay Holdings Limited	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
JPS61243059A (ja)	1985-04-19	1986-10-29	Konishi Kagaku Kogyo Kk	高純度４，４′−ジヒドロキシジフエニルスルホンの製造法
DE3603644A1 (de)	1986-02-06	1987-08-13	Metabowerke Kg	Spannfutter zum einspannen von bohrern oder schlagbohrern
US5208225A (en) *	1986-02-27	1993-05-04	Warner-Lambert Company	Compositions containing fixed combinations
ZA87332B (en)	1986-02-27	1987-08-26	Warner Lambert Co	Compositions containing fixed combinations
US5276022A (en)	1987-09-24	1994-01-04	Jencap Research Ltd.	Hormone preparation and method
US5256421A (en)	1987-09-24	1993-10-26	Jencap Research Ltd.	Hormone preparation and method
US5108995A (en)	1987-09-24	1992-04-28	Jencap Research Ltd.	Hormone preparation and method
CA1332227C (en)	1987-09-24	1994-10-04	Robert F. Casper	Oral contraceptive formulation
HU214598B (hu)	1987-09-24	1998-04-28	Jencap Research Ltd	Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására
HUT52382A (en)	1988-03-14	1990-07-28	Sandoz Ag	Process for producing pharmaceutical compositions comprising as active ingredient unsubstituted progestin in 19-position and estrogen in the given case
IE71203B1 (en)	1990-12-13	1997-02-12	Akzo Nv	Low estrogen oral contraceptives
FR2695826B1 (fr)	1992-09-21	1995-01-06	Theramex	Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
US5554601A (en)	1993-11-05	1996-09-10	University Of Florida	Methods for neuroprotection
US5552394A (en)	1994-07-22	1996-09-03	The Medical College Of Hampton Roads	Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6613757B1 (en)	1994-09-22	2003-09-02	Board Of Regents, The University Of Texas System	Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
SE9403389D0 (sv)	1994-10-06	1994-10-06	Astra Ab	Pharmaceutical composition containing derivattves of sex hormones
AU705644B2 (en)	1995-08-01	1999-05-27	Novartis Ag	Liposomal oligonucleotide compositions
FR2737411B1 (fr) *	1995-08-01	1997-10-17	Theramex	Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
US5888543A (en)	1996-07-26	1999-03-30	American Home Products Corporation	Oral contraceptives
FR2754179B1 (fr)	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
DE19739916C2 (de)	1997-09-11	2001-09-13	Hesch Rolf Dieter	Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
FR2776191B1 (fr) *	1998-03-23	2002-05-31	Theramex	Composition hormonale topique a effet systemique
WO2001030356A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
FR2814074B1 (fr) *	2000-09-15	2003-03-07	Theramex	Nouvelles compositions estro-progestatives topiques a effet systemique
ES2281551T3 (es) *	2001-11-15	2007-10-01	Pantarhei Bioscience B.V.	Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
US20080242650A1 (en)	2007-03-26	2008-10-02	Jean-Louis Thomas	Oral contraceptive regimen

1999
- 1999-10-25 WO PCT/FR1999/002588 patent/WO2001030356A1/fr not_active Ceased
- 1999-10-29 US US09/423,109 patent/US8168619B1/en not_active Expired - Fee Related
2000
- 2000-10-24 WO PCT/FR2000/002939 patent/WO2001030357A1/fr not_active Ceased
- 2000-10-24 IL IL14895300A patent/IL148953A0/xx active IP Right Grant
- 2000-10-24 DK DK00971476T patent/DK1227814T3/da active
- 2000-10-24 CA CA002389025A patent/CA2389025C/fr not_active Expired - Lifetime
- 2000-10-24 MX MXPA02004084A patent/MXPA02004084A/es active IP Right Grant
- 2000-10-24 HU HU0203721A patent/HU229382B1/hu not_active IP Right Cessation
- 2000-10-24 ES ES00971476T patent/ES2235967T3/es not_active Expired - Lifetime
- 2000-10-24 AP APAP/P/2002/002475A patent/AP1625A/en active
- 2000-10-24 PT PT00971476T patent/PT1227814E/pt unknown
- 2000-10-24 CN CNB008147841A patent/CN100553637C/zh not_active Expired - Fee Related
- 2000-10-24 EP EP00971476A patent/EP1227814B1/fr not_active Expired - Lifetime
- 2000-10-24 BR BRPI0014979A patent/BRPI0014979B8/pt not_active IP Right Cessation
- 2000-10-24 HK HK03100875.7A patent/HK1050472B/zh not_active IP Right Cessation
- 2000-10-24 NZ NZ518145A patent/NZ518145A/en not_active IP Right Cessation
- 2000-10-24 OA OA1200200119A patent/OA12072A/fr unknown
- 2000-10-24 AU AU10326/01A patent/AU777704B2/en not_active Ceased
- 2000-10-24 RU RU2002113652/15A patent/RU2261106C2/ru not_active IP Right Cessation
- 2000-10-24 PL PL356847A patent/PL199848B1/pl unknown
- 2000-10-24 CZ CZ20021427A patent/CZ303248B6/cs not_active IP Right Cessation
- 2000-10-24 KR KR1020027005259A patent/KR100623788B1/ko not_active Expired - Fee Related
- 2000-10-24 JP JP2001532775A patent/JP5036943B2/ja not_active Expired - Fee Related
- 2000-10-24 DE DE60017281T patent/DE60017281T2/de not_active Expired - Lifetime
- 2000-10-24 AT AT00971476T patent/ATE286400T1/de active
- 2000-10-24 SI SI200030615T patent/SI1227814T1/xx unknown
2002
- 2002-04-01 IL IL148953A patent/IL148953A/en unknown
- 2002-04-25 NO NO20021949A patent/NO327973B1/no not_active IP Right Cessation
- 2002-04-29 ZA ZA200203398A patent/ZA200203398B/en unknown
2012
- 2012-04-17 US US13/448,953 patent/US9084796B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2389025C (fr)	2009-12-08
SI1227814T1 (en)	2005-06-30
HK1050472A1 (en)	2003-06-27
NO20021949L (no)	2002-04-25
RU2002113652A (ru)	2004-03-27
AU777704B2 (en)	2004-10-28
PL199848B1 (pl)	2008-11-28
ATE286400T1 (de)	2005-01-15
KR20020057979A (ko)	2002-07-12
WO2001030356A1 (fr)	2001-05-03
ES2235967T3 (es)	2005-07-16
HU229382B1 (hu)	2013-11-28
US9084796B2 (en)	2015-07-21
HK1050472B (zh)	2005-07-08
AP2002002475A0 (en)	2002-06-30
DE60017281T2 (de)	2005-12-08
KR100623788B1 (ko)	2006-09-18
IL148953A (en)	2007-06-03
MXPA02004084A (es)	2003-08-20
JP5036943B2 (ja)	2012-09-26
AU1032601A (en)	2001-05-08
DE60017281D1 (de)	2005-02-10
BRPI0014979B8 (pt)	2021-05-25
CN1382053A (zh)	2002-11-27
CA2389025A1 (fr)	2001-05-03
US20130172300A1 (en)	2013-07-04
PL356847A1 (en)	2004-07-12
EP1227814B1 (fr)	2005-01-05
EP1227814A1 (fr)	2002-08-07
JP2003515531A (ja)	2003-05-07
DK1227814T3 (da)	2005-04-11
CN100553637C (zh)	2009-10-28
HUP0203721A3 (en)	2003-07-28
PT1227814E (pt)	2005-05-31
BRPI0014979B1 (pt)	2016-08-02
BR0014979A (pt)	2002-11-26
CZ20021427A3 (cs)	2002-08-14
WO2001030357A1 (fr)	2001-05-03
RU2261106C2 (ru)	2005-09-27
OA12072A (fr)	2006-05-04
AP1625A (en)	2006-07-04
HUP0203721A2 (hu)	2003-03-28
ZA200203398B (en)	2003-12-03
NZ518145A (en)	2005-01-28
NO20021949D0 (no)	2002-04-25
CZ303248B6 (cs)	2012-06-20
IL148953A0 (en)	2002-11-10
US8168619B1 (en)	2012-05-01

Legal Events

Date	Code	Title	Description
2020-05-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US9084796B2 (en)	2015-07-21	Hormonal composition and its use
CN102458386B (zh)	2016-04-06	用于紧急避孕的药物组合物
Erkkola et al.	2005	Role of progestins in contraception
US20100021529A1 (en)	2010-01-28	Step-down estrogen regimen for women receiving estrogen therapy
KR20160150113A (ko)	2016-12-28	연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
IL124472A (en)	2001-07-24	Process and kit for contraception of a female mammal that contains a mixture of gastagen and estrogen
JP2002509524A (ja)	2002-03-26	エストロゲン化合物とプロゲステロン様化合物よりなるホルモン組成物
US20230135376A1 (en)	2023-05-04	Multiphasic contraceptive and/or hormone replacement therapy
JP5484646B2 (ja)	2014-05-07	新規な避妊薬とその調製方法
KR20030043797A (ko)	2003-06-02	호르몬 조성물
정숙김 et al.	2017	Clinical use of oral contraceptives
HK1136506A (en)	2010-07-02	Pharmaceutical preparation for the alleviation of endometriosis
HK1129564B (en)	2017-01-20	Method of contraception based on a progestative and oestrogen
HK1170686B (en)	2017-05-05	Pharmaceutical composition for emergency contraception
HK1121685A (en)	2009-04-30	Hormonal composition consisting of an estrogen compound and of a progestational compound
HK1112200A (en)	2008-08-29	Contraceptive pharmaceutical preparation